+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Scleroderma Diagnostics and Therapeutics Market by Disease Type, by Drugs, by Diagnosis, by End-User, and By Region

  • PDF Icon

    Report

  • 200 Pages
  • March 2024
  • Region: Global
  • Erevna Healthcare
  • ID: 5941912
The global scleroderma diagnostics and therapeutics market size was estimated to be USD 2.54 billion in 2023 and is expected to reach USD 6.41 billion by 2034 with a CAGR of 8.76% during the forecast period 2024-2034. The increasing prevalence of scleroderma, advancements in diagnostic technologies, biotechnological and pharmaceutical innovations, collaborations and partnerships, awareness and early diagnosis campaigns, and government initiatives and funding will drive the market growth.

Global scleroderma case reports are increasing, which adds to the growing need for treatments and diagnostics. New treatment approaches and diagnostic techniques are being developed in the realm of autoimmune disorders, such as scleroderma, thanks to ongoing research and development efforts. Accurate diagnosis and early detection are improved by ongoing advancements in diagnostic technologies, including genetic testing, imaging methods, and biomarker discovery. For instance, Roche reported good Phase 2b findings in November 2023 for the treatment of early diffuse cutaneous systemic sclerosis (dcSSc) using Actemra (tocilizumab) in conjunction with methotrexate.

By disease type, the systemic scleroderma segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing prevalence of this form of the disease, advancements in early detection technologies, and the development of targeted therapeutics that address the complex pathophysiology associated with systemic scleroderma. For instance, in October 2023, Boehringer Ingelheim established the Boehringer Ingelheim Scleroderma Clinical Research Center in collaboration with Cedars-Sinai Medical Center. Additionally, the localized scleroderma segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on early diagnosis and intervention, advancements in localized treatment modalities, and a growing awareness of the disease among healthcare professionals and the general public.

By drugs, the immunosuppressive agents segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing adoption of these medications for managing autoimmune responses and inflammation associated with scleroderma. For instance, in September 2023, the FDA approved Bristol-Myers Squibb's Ocrevus (ocrelizumab) to treat anti-MAG positive primary progressive multiple sclerosis (PPMS), a condition that may also help certain people with sickle cell disease. Additionally, the endothelin receptor antagonists (ERAs) and Phosphodiesterase-5 inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their effectiveness in managing vascular complications associated with scleroderma.

By diagnosis, the imaging techniques segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the increasing adoption of advanced diagnostic technologies such as high-resolution ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans. For instance, AbbVie presented findings at the American College of Rheumatology (ACR) meeting in December 2023 that suggested Upadacitinib could be useful in reducing skin stiffening in individuals with systemic sclerosis. Additionally, the blood tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on precision diagnostics, advancements in biomarker identification, and the growing recognition of blood-based assays as reliable tools for early detection and monitoring of scleroderma.

By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global scleroderma diagnostics and therapeutics market in 2023 owing to the centralized and comprehensive healthcare services offered by hospitals, making them primary centers for the diagnosis, treatment, and management of scleroderma patients. For instance, Pfizer and the Scleroderma Research Foundation established a partnership in November 2023 to establish a patient registry aimed at advancing clinical trials and research related to SSc. Additionally, the home healthcare segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient-centered care, advancements in telemedicine and remote monitoring technologies, and a growing preference for managing chronic conditions, such as scleroderma, in the comfort of patients' homes.

North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increasing prevalence of scleroderma, robust research and development activities, and a high level of awareness among both healthcare professionals and the general population. For instance, in July 2023, Boehringer Ingelheim released the findings of a research showing that nintedanib may help people with sickle cell lung disease. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of scleroderma, a rising prevalence of autoimmune diseases, and a growing focus on enhancing healthcare infrastructure.

This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.

Report Scope:

  • Base Year: 2023
  • Forecast Period: 2024-2034
  • Study Coverage
  • Market Forecast by Disease Type, Drugs, Diagnosis, End-User
  • Market Forecast for 5 Regions and 17+ Countries
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
  • Exhaustive Company Profiles of the Top 10+ Major Market Players
  • 20% Free Customization Available to Meet Your Exact Requirement.

Segmentation: Scleroderma Diagnostics and Therapeutics Market Report 2023 - 2034

Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Disease Type 2023 - 2034 (Revenue USD Bn)

  • Localized Scleroderma
  • Systemic Scleroderma

Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Drugs 2023 - 2034 (Revenue USD Bn)

  • Corticosteroids
  • Immunosuppressive Agents
  • Endothelin Receptor Antagonists
  • Calcium Channel Blockers
  • PDE-5 Inhibitors
  • Chelating Agents
  • Prostacyclin Analogues
  • Others

Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn)

  • Antibodies Tests/Blood Tests
  • Capillaroscopy
  • Cardiac Diagnosis
  • Gastrointestinal Diagnosis
  • Imaging (CT and MRI)
  • Pulmonary Diagnosis
  • Skin Viscoelasticity
  • General

Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

  • Hospitals
  • Ambulatory Surgery Centers
  • Home Healthcare
  • Research Laboratories

Scleroderma Diagnostics and Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • GCC
Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
2. Introduction
2.1. Market Definition
2.2. Global Scleroderma Diagnostics and Therapeutics Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. Scleroderma Diagnostics and Therapeutics Market: Disease Type Estimates & Trend Analysis
7.1. Disease Type Segment Opportunity Analysis
7.2. Localized Scleroderma
7.2.1. Localized Scleroderma Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3. Systemic Scleroderma
7.3.1. Systemic Scleroderma Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8. Scleroderma Diagnostics and Therapeutics Market: Drugs Estimates & Trend Analysis
8.1. Drugs Segment Opportunity Analysis
8.2. Corticosteroids
8.2.1. Corticosteroids Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.3. Immunosuppressive Agents
8.3.1. Immunosuppressive Agents Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.4. Endothelin Receptor Antagonists
8.4.1. Endothelin Receptor Antagonists Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.5. Calcium Channel Blockers
8.5.1. Calcium Channel Blockers Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.6. PDE-5 Inhibitors
8.6.1. PDE-5 Inhibitors Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.7. Chelating Agents
8.7.1. Chelating Agents Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.8. Prostacyclin Analogues
8.8.1. Prostacyclin Analogues Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.9. Others
8.9.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9. Scleroderma Diagnostics and Therapeutics Market: Diagnosis Estimates & Trend Analysis
9.1. Diagnosis Segment Opportunity Analysis
9.2. Antibodies Tests/Blood Tests
9.2.1. Antibodies Tests/Blood Tests Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.3. Capillaroscopy
9.3.1. Capillaroscopy Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.4. Cardiac Diagnosis
9.4.1. Cardiac Diagnosis Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.5. Gastrointestinal Diagnosis
9.5.1. Gastrointestinal Diagnosis Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.6. Imaging (CT and MRI)
9.6.1. Imaging (CT and MRI) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.7. Pulmonary Diagnosis
9.7.1. Pulmonary Diagnosis Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.8. Skin Viscoelasticity
9.8.1. Skin Viscoelasticity Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.9. General
9.9.1. General Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10. Scleroderma Diagnostics and Therapeutics Market: End-User Estimates & Trend Analysis
10.1. End-User Segment Opportunity Analysis
10.2. Hospital
10.2.1. Hospital Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10.3. Ambulatory Surgery Centers Ambulatory Surgery Centers
10.3.1. Ambulatory Surgery Centers Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10.4. Home Healthcare
10.4.1. Home Healthcare Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10.5. Research Laboratories
10.5.1. Research Laboratories Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
11. Regional Market Analysis
11.1. Regional Market Opportunity Analysis
12. North America Scleroderma Diagnostics and Therapeutics Market
12.1. North America Scleroderma Diagnostics and Therapeutics Market
12.1.1. North America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.1.2. North America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
12.1.3. North America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
12.1.4. North America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
12.1.5. North America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
12.1.6. North America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
12.2. U.S. Global Scleroderma Diagnostics and Therapeutics Market
12.2.1. U.S. Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.2.2. U.S. Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
12.2.3. U.S. Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
12.2.4. U.S. Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
12.2.5. U.S. Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
12.3. Canada Global Scleroderma Diagnostics and Therapeutics Market
12.3.1. Canada Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.3.2. Canada Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
12.3.3. Canada Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
12.3.4. Canada Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
12.3.5. Canada Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
13. Europe Global Scleroderma Diagnostics and Therapeutics Market
13.1. Europe Global Scleroderma Diagnostics and Therapeutics Market
13.1.1. Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.1.2. Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
13.1.3. Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
13.1.4. Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
13.1.5. Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
13.1.6. Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
13.2. Germany Global Scleroderma Diagnostics and Therapeutics Market
13.2.1. Germany Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.2.2. Germany Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
13.2.3. Germany Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
13.2.4. Germany Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
13.2.5. Germany Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
13.3. UK Global Scleroderma Diagnostics and Therapeutics Market
13.3.1. UK Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.3.2. UK Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
13.3.3. UK Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
13.3.4. UK Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
13.3.5. UK Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
13.4. France Global Scleroderma Diagnostics and Therapeutics Market
13.4.1. France Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.4.2. France Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
13.4.3. France Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
13.4.4. France Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
13.4.5. France Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
13.5. Spain Global Scleroderma Diagnostics and Therapeutics Market
13.5.1. Spain Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.5.2. Spain Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
13.5.3. Spain Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
13.5.4. Spain Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
13.5.5. Spain Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
13.6. Italy Global Scleroderma Diagnostics and Therapeutics Market
13.6.1. Italy Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.6.2. Italy Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
13.6.3. Italy Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
13.6.4. Italy Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
13.6.5. Italy Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
13.7. Rest of Europe Global Scleroderma Diagnostics and Therapeutics Market
13.7.1. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.7.2. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
13.7.3. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
13.7.4. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
13.7.5. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
14. Asia Pacific Global Scleroderma Diagnostics and Therapeutics Market
14.1. Asia Pacific Global Scleroderma Diagnostics and Therapeutics Market
14.1.1. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.1.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
14.1.3. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
14.1.4. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
14.1.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
14.1.6. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
14.2. Japan Global Scleroderma Diagnostics and Therapeutics Market
14.2.1. Japan Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.2.2. Japan Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
14.2.3. Japan Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
14.2.4. Japan Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
14.2.5. Japan Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
14.3. China Global Scleroderma Diagnostics and Therapeutics Market
14.3.1. China Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.3.2. China Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
14.3.3. China Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
14.3.4. China Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
14.3.5. China Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
14.4. India Global Scleroderma Diagnostics and Therapeutics Market
14.4.1. India Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.4.2. India Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
14.4.3. India Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
14.4.4. India Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
14.4.5. India Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
14.5. South Korea Global Scleroderma Diagnostics and Therapeutics Market
14.5.1. South Korea Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.5.2. South Korea Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
14.5.3. South Korea Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
14.5.4. South Korea Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
14.5.5. South Korea Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
14.6. Australia Global Scleroderma Diagnostics and Therapeutics Market
14.6.1. Australia Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.6.2. Australia Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
14.6.3. Australia Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
14.6.4. Australia Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
14.6.5. Australia Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
14.7. Rest of Asia Pacific Global Scleroderma Diagnostics and Therapeutics Market
14.7.1. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.7.2. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
14.7.3. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
14.7.4. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
14.7.5. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
15. Latin America Global Scleroderma Diagnostics and Therapeutics Market
15.1. Latin America Global Scleroderma Diagnostics and Therapeutics Market
15.1.1. Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.1.2. Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
15.1.3. Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
15.1.4. Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
15.1.5. Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
15.1.6. Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
15.2. Brazil Global Scleroderma Diagnostics and Therapeutics Market
15.2.1. Brazil Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.2.2. Brazil Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
15.2.3. Brazil Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
15.2.4. Brazil Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
15.2.5. Brazil Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
15.3. Mexico Global Scleroderma Diagnostics and Therapeutics Market
15.3.1. Mexico Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.3.2. Mexico Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
15.3.3. Mexico Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
15.3.4. Mexico Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
15.3.5. Mexico Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
15.4. Argentina Global Scleroderma Diagnostics and Therapeutics Market
15.4.1. Argentina Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.4.2. Argentina Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
15.4.3. Argentina Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
15.4.4. Argentina Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
15.4.5. Argentina Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
15.5. Rest of Latin America Global Scleroderma Diagnostics and Therapeutics Market
15.5.1. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.5.2. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
15.5.3. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
15.5.4. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
15.5.5. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
16. MEA Global Scleroderma Diagnostics and Therapeutics Market
16.1. MEA Global Scleroderma Diagnostics and Therapeutics Market
16.1.1. MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.1.2. MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
16.1.3. MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
16.1.4. MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
16.1.5. MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
16.1.6. MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
16.2. GCC Global Scleroderma Diagnostics and Therapeutics Market
16.2.1. GCC Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.2.2. GCC Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
16.2.3. GCC Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
16.2.4. GCC Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
16.2.5. GCC Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
16.3. South Africa Global Scleroderma Diagnostics and Therapeutics Market
16.3.1. South Africa Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.3.2. South Africa Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
16.3.3. South Africa Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
16.3.4. South Africa Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
16.3.5. South Africa Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
16.4. Rest of MEA Global Scleroderma Diagnostics and Therapeutics Market
16.4.1. Rest of MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.4.2. Rest of MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Disease Type, 2023-2034 (Revenue USD Bn)
16.4.3. Rest of MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Drugs, 2023-2034 (Revenue USD Bn)
16.4.4. Rest of MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By Diagnosis, 2023-2034 (Revenue USD Bn)
16.4.5. Rest of MEA Scleroderma Diagnostics and Therapeutics Market Size and Forecast, By End-User, 2023-2034 (Revenue USD Bn)
17. Competitor Analysis
17.1. Company Market Share Analysis, 2023
17.2. Major Recent Developments
18. Company Profiles
18.1. Boehringer Ingelheim International GmbH
18.2. Bristol-Myers Squibb Company
18.3. F. Hoffmann-La Roche Ltd.
18.4. GlaxoSmithKline plc
18.5. Johnson & Johnson Services, Inc.
18.6. Eli Lilly and Company
18.7. Pfizer Inc.
18.8. Novartis International AG
18.9. Sanofi
18.10. Abbvie Inc.
18.11. Genentech, Inc. (a member of the Roche Group)
18.12. Actelion Pharmaceuticals Ltd. (a Janssen Pharmaceutical Company of Johnson & Johnson)
18.13. Celgene Corporation (acquired by Bristol Myers Squibb)
18.14. Mylan N.V.
18.15. Biogen Inc.
19. Conclusion20. Recommendations

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi
  • Abbvie Inc.
  • Genentech Inc. (a member of the Roche Group)
  • Actelion Pharmaceuticals Ltd. (a Janssen Pharmaceutical Company of Johnson & Johnson)
  • Celgene Corporation (acquired by Bristol Myers Squibb)
  • Mylan N.V.
  • Biogen Inc.

Table Information